Videos

SECuRE Trial TT

Copper-67 (Cu-67 or 67Cu) in Cancer Therapy: Current Developments and Future Potential - Alan Taylor Details Oliver Sartor speaks with Alan Taylor about advances in radiopharmaceuticals for cancer treatment. Dr. Taylor discusses Clarity's focus on copper isotopes, particularly Copper-67 (Cu-67 or 67 Cu), for targeted therapy. He explains the company's innovative bisPSMA technology, which offers improved tumor uptake and retention compared to conventional PSMA agents. Dr. Taylor highlights Clarity's work...
SECuRE Trial: Copper-67 SAR-bisPSMA Therapy for Prostate Cancer - Geoffrey Johnson Details Zach Klaassen and Geoffrey Johnson discuss the SECuRE trial, a phase 1-2 dose escalation expansion study of a PSMA-targeted radiopharmaceutical for prostate cancer using copper 67. This innovative therapy boasts a unique chelator, enhancing drug delivery and reducing systemic leakage. Early results demonstrate promising efficacy and safety, with notable responses observed in patients, including co...